NZ527655A - Combination of a taxane (docetaxel) and a cyclin-dependent kinase inhibitor (flavopiridol) - Google Patents

Combination of a taxane (docetaxel) and a cyclin-dependent kinase inhibitor (flavopiridol)

Info

Publication number
NZ527655A
NZ527655A NZ527655A NZ52765502A NZ527655A NZ 527655 A NZ527655 A NZ 527655A NZ 527655 A NZ527655 A NZ 527655A NZ 52765502 A NZ52765502 A NZ 52765502A NZ 527655 A NZ527655 A NZ 527655A
Authority
NZ
New Zealand
Prior art keywords
flavopiridol
docetaxel
taxane
cyclin
combination
Prior art date
Application number
NZ527655A
Other languages
English (en)
Inventor
Marie-Christine Bissery
Original Assignee
Aventis Pharma S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma S filed Critical Aventis Pharma S
Publication of NZ527655A publication Critical patent/NZ527655A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ527655A 2001-03-23 2002-03-22 Combination of a taxane (docetaxel) and a cyclin-dependent kinase inhibitor (flavopiridol) NZ527655A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US27794801P 2001-03-23 2001-03-23
US30269201P 2001-07-05 2001-07-05
US33491601P 2001-12-04 2001-12-04
PCT/EP2002/004083 WO2002076484A2 (en) 2001-03-23 2002-03-22 Combination of a taxane and a cyclin-dependent kinase inhibitor

Publications (1)

Publication Number Publication Date
NZ527655A true NZ527655A (en) 2006-03-31

Family

ID=27402954

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ527655A NZ527655A (en) 2001-03-23 2002-03-22 Combination of a taxane (docetaxel) and a cyclin-dependent kinase inhibitor (flavopiridol)

Country Status (33)

Country Link
US (2) US20020182204A1 (enExample)
EP (1) EP1372652B1 (enExample)
JP (1) JP2004521140A (enExample)
KR (1) KR100879712B1 (enExample)
CN (1) CN1498107A (enExample)
AR (1) AR034222A1 (enExample)
AT (1) ATE395917T1 (enExample)
AU (1) AU2002312815B2 (enExample)
BR (1) BR0208221A (enExample)
CA (1) CA2441441C (enExample)
CY (1) CY1110449T1 (enExample)
CZ (1) CZ301423B6 (enExample)
DE (1) DE60226710D1 (enExample)
DK (1) DK1372652T3 (enExample)
EA (1) EA007815B1 (enExample)
ES (1) ES2305253T3 (enExample)
HR (1) HRPK20030766B3 (enExample)
HU (1) HU229258B1 (enExample)
IL (2) IL158058A0 (enExample)
ME (1) MEP16408A (enExample)
MX (1) MXPA03007743A (enExample)
NO (1) NO332441B1 (enExample)
NZ (1) NZ527655A (enExample)
PE (1) PE20020907A1 (enExample)
PL (1) PL206118B1 (enExample)
PT (1) PT1372652E (enExample)
RS (1) RS50681B (enExample)
SI (1) SI1372652T1 (enExample)
SK (1) SK287481B6 (enExample)
TW (1) TWI355935B (enExample)
UY (1) UY27220A1 (enExample)
WO (1) WO2002076484A2 (enExample)
ZA (1) ZA200307381B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003217982A1 (en) * 2002-03-06 2003-09-22 The Medical Research And Education Trust Botanical extract compositions with anti-cancer or phytoestrogenic activity comprising wogonin, isoliquiritigenin and/or coumestrol
AU2003287081A1 (en) * 2002-10-16 2004-05-04 Ilex Products, Inc. Clofarabine and taxane chemotherapy combination
EP1558242B1 (en) * 2002-11-06 2008-12-24 Cyclacel Limited Combination comprising docetaxel and a cdk inhibitor
ES2390237T3 (es) * 2006-02-10 2012-11-07 Nerviano Medical Sciences S.R.L. Combinaciones que comprenden un inhibidor de cdk y un anticuerpo anti-factor de crecimiento o un agente antimitótico
BR112013012313A2 (pt) * 2010-11-19 2019-09-24 Piramal Enterprises Limited combinação farmacêutica de paclitaxel e um inibidor de cdk
ME03589B (me) 2011-04-01 2020-07-20 Astrazeneca Ab Terapeutski tretman
MX367640B (es) 2011-11-30 2019-08-29 Astrazeneca Ab Tratamiento combinado del cáncer.
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
MX9102128A (es) * 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
EP0888458A4 (en) * 1996-02-20 2004-05-06 Sloan Kettering Institutefor C COMBINATION OF PKC INHIBITORS AND THERAPEUTIC AGENTS FOR TREATING CANCER

Also Published As

Publication number Publication date
NO20034124L (no) 2003-09-16
TWI355935B (en) 2012-01-11
UY27220A1 (es) 2002-09-30
PT1372652E (pt) 2008-07-24
SK11692003A3 (sk) 2004-03-02
ATE395917T1 (de) 2008-06-15
DE60226710D1 (de) 2008-07-03
CY1110449T1 (el) 2015-04-29
HUP0303589A2 (hu) 2004-03-01
WO2002076484A3 (en) 2003-01-03
KR100879712B1 (ko) 2009-01-22
MXPA03007743A (es) 2004-11-12
BR0208221A (pt) 2004-03-02
EA007815B1 (ru) 2007-02-27
EP1372652B1 (en) 2008-05-21
IL158058A (en) 2010-02-17
RS50681B (sr) 2010-06-30
ZA200307381B (en) 2005-03-30
CA2441441C (en) 2009-05-26
KR20030086318A (ko) 2003-11-07
JP2004521140A (ja) 2004-07-15
PL206118B1 (pl) 2010-07-30
HUP0303589A3 (en) 2007-05-02
US20060128640A1 (en) 2006-06-15
CN1498107A (zh) 2004-05-19
SI1372652T1 (sl) 2008-10-31
YU69503A (sh) 2006-08-17
US20020182204A1 (en) 2002-12-05
PL367702A1 (en) 2005-03-07
CA2441441A1 (en) 2002-10-03
EA200301053A1 (ru) 2004-02-26
ES2305253T3 (es) 2008-11-01
SK287481B6 (sk) 2010-11-08
DK1372652T3 (da) 2008-09-22
CZ20032551A3 (en) 2004-07-14
HRPK20030766B3 (en) 2006-11-30
NO20034124D0 (no) 2003-09-16
PE20020907A1 (es) 2002-12-19
NO332441B1 (no) 2012-09-17
HRP20030766A2 (en) 2005-06-30
EP1372652A2 (en) 2004-01-02
HU229258B1 (en) 2013-10-28
AU2002312815B2 (en) 2006-08-24
CZ301423B6 (cs) 2010-02-24
MEP16408A (en) 2010-10-10
AR034222A1 (es) 2004-02-04
WO2002076484A2 (en) 2002-10-03
IL158058A0 (en) 2004-03-28

Similar Documents

Publication Publication Date Title
GEP20053511B (en) ) β-Carboline Derivatives Useful as Inhibitors of Phosphodiesterase
PL372925A1 (en) Prevention and treatment of restenosis by local administration of drug
GB0005251D0 (en) Therapeutic compounds
NO954996D0 (no) Anvendelse av nona- og dekapeptider for fremstilling av et legemiddel for behandling av AIDS
DE60230632D1 (de) Pharmazeutische kombinationen von oxycodon und naloxon
HUP0301121A3 (en) Topical pharmaceutical formulations and methods of treatment
EP1255765A4 (en) PHARMACEUTICAL COMPOSITIONS AND TREATMENTS FOR RHUMATOID POLYARTHRITIS
AR028426A1 (es) Una composicion farmaceutica y procedimiento de tratamiento de enfermedades de disfunsion cognitiva en un mamifero
HUP0401174A3 (en) Ecteinascidin analogues, their use in the preparation of a medicament for treatment of cancer and pharmaceutical compositions containing the compounds
IL161744A (en) Use of zd6474 and taxane in the manufacture of a medicament for the treatment of cancer and pharmaceutical compositions and kits comprising such compounds
GEP20053510B (en) Substituted Pyrrolopyridinone Derivatives Useful as Phosphodiesterase Inhibitors
TR200103819T2 (tr) kanser tedavisinde ET743 terkipleri ve kullanımları
TNSN04217A1 (en) Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer
IS7006A (is) Tvívetnis 3-piperidínóprópíófenon og lyf sem innihalda téð efnasambönd
NO20042208L (no) Vaginalt administrerte anti-dysrytmiske midler for behandling av bekkensmerter
AR034343A1 (es) Combinaciones farmaceuticas
HUP0301460A3 (en) Use of antiprogestins for producing pharmaceutical compositions for prohylaxis and treatment of hormone-dependent diseases
JO2178B1 (en) Treatment of emphysema using rar selective retinoid antagonists
GB0020504D0 (en) Therapeutic method
HUP0204050A3 (en) Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone
HUP0300402A3 (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain and pharmaceutical compositions containing them
MXPA04001912A (es) Aminobenzofenonas novedosas.
HUP0400924A3 (en) Use of 2,5-dihydroxybenzenesulfphonic acid derivatives in the production of a medicament used to potentiate the effect of other drugs in the treatment of erectile dysfunction
IL158058A (en) Combination of a taxane and a cyclin-dependent kinase inhibitor
GB0003201D0 (en) Method to potentiate the therapeutic efficacy of taxane and derivatives thereof

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
LAPS Patent lapsed